Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 17  |  Issue : 3  |  Page : 784-789

Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study


1 Nursing Department, The Second Hospital of Shandong University; Interventional Oncology Institute, Shandong University, Jinan, Shandong Province, China
2 Dean' s Office, Jinan Vocational College of Nursing, Jinan, Shandong Province, China
3 Interventional Oncology Institute, Shandong University; Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, Shandong Province, China
4 Interventional Oncology Institute, Shandong University; Department of Interventional Medicine, Shandong Cancer Hospital, Jinan, Shandong Province, China
5 Interventional Oncology Institute, Shandong University; Department of Sterilization and Supply, The Second Hospital of Shandong University, Jinan, Shandong Province, China

Correspondence Address:
Shuzhi Mao
Department of Sterilization and Supply, Second Hospital of Shandong University, Jinan, Shandong Province, CN-250 033
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.jcrt_467_21

Rights and Permissions

Purpose: To analyze the effects of trans-jugular intrahepatic portosystemic shunt (TIPS) on portal hypertension and liver function in patients with hepatocellular carcinoma (HCC). Materials and Methods: Thirteen patients with hemorrhage caused by portal hypertension and HCC who received TIPS and antitumor treatment were retrospectively analyzed. Trans-arterial chemoembolization, microwave ablation, target therapy, and immunetherapy or combined therapy were performed to treat HCC. Child-Pugh score was applied to estimate liver functions before and after TIPS. Shunting patency, overall survival (OS), and progression-free survival were analyzed. Results: The median age was 58 (interquartile range: 52.5–62.5) years. The ratio with ascites before and after TIPS was 84.6% (11/13) and 7.7% (1/13), with P < 0.001. The ratio with Child-Pugh A before and after TIPS were 61.5% (8/13) and 84.6% (11/13) respectively, with P = 0.179. Mean portal vein pressure before and after TIPS was 27.85 ± 7.02 mmHg and 16.23 ± 6.61 mmHg, respectively, with P = 0.001. Two-year shunting patency rate was 61.5%. Median OS was 29.8 ± 11.5 months (95% confidence interval [CI] 22.8–36.7), and median progression-free survival was 20.2 ± 13.2 months (95% CI 12.2–28.1). Conclusion: TIPS could reduce ascites, down-regulate the Child-Pugh score, and give a chance for further anti-tumor therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed222    
    Printed0    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal